Therapy

Why?

• Abciximab increases death within 48 hours, major bleeding and thrombocytopenia in acute coronary syndrome (ST depression or a positive troponin), without clearly reducing death, myocardial infarction or the need for revascularisation within 30 days. ^a

 Abciximab increases early death, major bleeding and thrombocytopenia

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
acute coronary syndrome  a	abciximab	placebo	death at 48 hours	0.31%	-160% (-450% to -20%)	-210 (-630 to -130)
			major bleed at 30 days	0.27%	-200% (-570% to -35%)	-190 (-450 to -120)
			thrombocytopenia at 30 days	0.039%	-3800% (-28000% to -440%)	-68 (-89 to -56)